Shares of Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) rose 7.4% during trading on Tuesday . The company traded as high as $5.50 and last traded at $5.50. Approximately 3,488 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 10,667 shares. The stock had previously closed at $5.12.
Idorsia Price Performance
The business’s fifty day moving average price is $4.25 and its 200 day moving average price is $4.49.
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
See Also
- Five stocks we like better than Idorsia
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
